Covered recipient · General Payments record
JAMES W SHORE
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,147.39
- Reported across 124 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $329.18 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $234.15 | 11 |
| Lilly USA, LLC | $30.10 | 2 |
| Otsuka America Pharmaceutical, Inc. | $27.09 | 1 |
| Exact Sciences Corporation | $19.97 | 1 |
| ABBVIE INC. | $17.87 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.87 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106091250 | CMS |
| Exact Sciences Corporation | $19.97 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114896531 | CMS |
| Lilly USA, LLC | $14.76 | 04/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135025328 | CMS |
| Lilly USA, LLC | $15.34 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135025330 | CMS |
| Novo Nordisk Inc | $21.16 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097639373 | CMS |
| Novo Nordisk Inc | $20.80 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096954369 | CMS |
| Novo Nordisk Inc | $21.17 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097260981 | CMS |
| Novo Nordisk Inc | $22.23 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097348142 | CMS |
| Novo Nordisk Inc | $20.20 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096976320 | CMS |
| Novo Nordisk Inc | $21.17 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096577567 | CMS |
| Novo Nordisk Inc | $21.17 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097807858 | CMS |
| Novo Nordisk Inc | $21.69 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096581464 | CMS |
| Novo Nordisk Inc | $22.23 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096795418 | CMS |
| Novo Nordisk Inc | $21.17 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096775463 | CMS |
| Novo Nordisk Inc | $21.16 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096748127 | CMS |
| Otsuka America Pharmaceutical, Inc. | $27.09 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118982083 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.